- Profile
- Personal Information
- Publications
Experts in Business and Management
Gerhard J. Barone Dr. Hanumant Yadav Jack Jonck DOÄžANAY, Mehmet Mete Bernardo Balboni G. Eddy Birrer Cem Behar Bin Ke Cengiz Kallek Michael Frese Engin Akarli Andrew M. Brajcich Robert Lee Ensar Gul Irene Elisabeth De Pater RUOLIAN FANG REMUS ILIES Geraldo Cerqueiro Timothy G. Coville Ghee Soon Lim View MoreDr. Willard Dere joined our Board in July 2016. He serves as the Professor of Internal Medicine; B. Lue and Hope S. Bettilyon Presidential Endowed Chair in Internal Medicine for Diabetes Research, Executive Director of Personalized Health, and Co-Principal Investigator of the Center for Clinical and Translational Science at the University of Utah Health Sciences Center. Prior to re-joining academia in November 2014, Dr. Dere was in the biopharmaceutical industry for 25 years. He joined Amgen in 2003 where he held multiple roles including head of global development, international research and development, and both corporate and international chief medical officer. He led the development programs for Prolia and several other programs, and retired from Amgen in October 2014. He began his career at Eli Lilly in 1989, and held a number of different global roles in clinical pharmacology, regulatory affairs, and both early-stage translational, and late-stage clinical research. While at Eli Lilly, he led the development of Evista and Forteo. Dr. Willard Dere joined our Board in July 2016. He serves as the Professor of Internal Medicine; B. Lue and Hope S. Bettilyon Presidential Endowed Chair in Internal Medicine for Diabetes Research, Executive Director of Personalized Health, and Co-Principal Investigator of the Center for Clinical and Translational Science at the University of Utah Health Sciences Center. Prior to re-joining academia in November 2014, Dr. Dere was in the biopharmaceutical industry for 25 years. He joined Amgen in 2003 where he held multiple roles including head of global development, international research and development, and both corporate and international chief medical officer. He led the development programs for Prolia and several other programs, and retired from Amgen in October 2014. He began his career at Eli Lilly in 1989, and held a number of different global roles in clinical pharmacology, regulatory affairs, and both early-stage translational, and late-stage clinical research. While at Eli Lilly, he led the development of Evista and Forteo.
Business